Myriad Genetics News

Piper Sandler Sticks to Their Hold Rating for Myriad Genetics (MYGN)

TipRanksMar 6 07:36 ET

Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty

TipRanksMar 1 01:03 ET

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

TipRanksFeb 28 07:32 ET

Myriad Genetics: A Sell Rating Amidst Profitability and Growth Concerns

TipRanksFeb 28 06:57 ET

Myriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious Outlook

TipRanksFeb 27 21:55 ET

Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)

TipRanksFeb 8 07:39 ET

Myriad Genetics Analyst Ratings

BenzingaJan 30 08:58 ET

Myriad Genetics Analyst Ratings

BenzingaJan 29 10:33 ET

BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating

MT NewswiresJan 29 10:32 ET

Myriad Genetics Analyst Ratings

BenzingaDec 21, 2023 05:33 ET

Myriad Genetics Analyst Ratings

BenzingaDec 19, 2023 11:07 ET

Guggenheim Initiates Coverage On Myriad Genetics With Buy Rating, Announces Price Target of $23

BenzingaDec 14, 2023 06:36 ET

Myriad Genetics Analyst Ratings

BenzingaDec 13, 2023 11:56 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Myriad Genetics (MYGN), Revolution Medicines (RVMD) and Demant (OtherWILLF)

TipRanksNov 8, 2023 07:22 ET

Myriad Genetics: Hold Rating Amid Strong Revenues and Cautious Optimism for Future Growth

TipRanksNov 8, 2023 00:34 ET

Myriad Genetics Analyst Ratings

BenzingaNov 7, 2023 15:14 ET

Goldman Sachs Reaffirms Their Buy Rating on Myriad Genetics (MYGN)

TipRanksNov 7, 2023 09:06 ET

Hold Rating on Myriad Genetics: Balancing Solid Performance With Valuation Concerns

TipRanksNov 7, 2023 00:55 ET

BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating

MT NewswiresOct 20, 2023 10:48 ET

Bank of America Securities Keeps Their Sell Rating on Myriad Genetics (MYGN)

TipRanksSep 21, 2023 04:39 ET